Evidence map›Paper›PMID 41561157›Full record

ArticleFrontiers in physiology2025

Assessing insulin resistance: the triglyceride-glucose index as a predictor of survival in nasopharyngeal carcinoma.

Xin Hua, Fei Xu, Xu-Xin Lin, Yong-Miao Lin, Zhi-Qing Long, Si-Fen Wang, Fang-Fang Duan, Chao Zhang, Xin Huang, Wen Xia and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xin Hua *Department of Radiation Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Fei Xu *Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.
Xu-Xin Lin *Department of Radiation Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Yong-Miao LinSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Zhi-Qing LongSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Si-Fen WangSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Fang-Fang DuanSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Chao ZhangSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Xin HuangSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Wen XiaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Wen-Chao LiDepartment of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
Ao-Qiang ChenSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
De-Huan XieDepartment of Radiation Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Sha-Sha DuDepartment of Radiation Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The triglyceride-glucose (TyG) index, a simple marker of insulin resistance, has shown prognostic value in various malignancies. However, its predictive utility for survival in nasopharyngeal carcinoma (NPC) patients remains largely unexamined. This study aimed to assess the prognostic value of the TyG index and to develop novel predictive models for survival outcomes in NPC. Methods: We retrospectively analyzed 833 NPC patients treated with concurrent chemoradiotherapy (CCRT). All patients were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM staging system. The TyG index was calculated as ln (fasting triglycerides × fasting glucose). Primary and secondary endpoints were overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS), respectively. We utilized univariate and multivariate Cox proportional hazards models to identify independent prognostic factors and subsequently constructed and validated nomograms. Results: A low TyG index was significantly associated with better survival outcomes, serving as an independent predictor for OS (hazard ratio [HR] = 0.534; P = 0.007), LRFS (HR = 0.423; P < 0.001), and DMFS (HR = 0.575; P = 0.010) in multivariate analysis. The newly developed nomograms demonstrated favorable discriminative performance, significantly outperforming the conventional TNM staging system (concordance index [C-index] for OS: 0.722 vs. 0.634). Conclusion: The TyG index is a readily available, powerful prognostic biomarker for NPC patients. Incorporating the TyG index into prognostic nomograms offers a superior tool for individualized risk stratification and treatment planning, representing a valuable advancement over traditional staging systems.

Indexed as

concurrent chemoradiotherapynasopharyngeal carcinomanomogramprognosistriglyceride-glucose index

Identifiers

PMID41561157
PMCPMC12812891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.